Throughout the study, subjects were monitored for adverse events (AEs).
Throughout the study, subjects used cannabis as they typically would.
Throughout the study, subjects completed equivalent DSST variants, with no individual taking the same form more than once.
Throughout the study, subjects completed equivalent SCT variants, with no individual taking the same form more than once.
Throughout the study, subjects had to recall equivalent word-list variants, with no individual hearing the same list more than once.
During the 2-week run-in period and throughout the study, subjects continued their usual COPD medication and withdrew statin therapy for 4 weeks prior to the study entry if they were taking regular treatment.
Throughout the study, subjects were evaluated by an investigator if they developed high fever (oral temperature > 39°C/102.2°F) or if any fever ≥ 38°C/100.4°F (oral temperature) was measured at least once on two successive days.
While it is unknown whether the PR in this current population has resurfaced, as it does with normal advanced aging, or if they have been present throughout the subjects' life it can possibly indicate CNS disruption.
The inclusion of qualitative exposure assessment methods to better estimate the amount of fuel used throughout the subjects' lives, and the integration of quantitative exposure assessment methodologies to measure the subjects' doses are crucial to answer open research questions, such as dose response relationships.
Throughout the study, the subjects undertook periodic self-assessment on a normal diet.
